陆宇， 医学博士， 研究员， 首都医科大学教授， 博士生导师。首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所药物学研究室主任。 任中国药理学会化疗药理专业委员会副主任委员兼秘书长，中国药学会抗生素专业委员会委员兼秘书长、中国防痨协会标准化专业委员会常委等。研究方向：药效学与药代动力学;致力于抗结核药物药理学研究，建立了国内一流、 国际公认的抗结核新药药效学平台;主持国家传染病科技重大专项、国家新药创制重大专项、国家自然科学基金面上项目、北京市自然科学基金，国际合作课题等多项。以第一作者或者通讯作者发表学术论文 100余篇， 获北京市科技进步奖一项,国家发明专利 3 项。已指导及联合培养研究生17 名;在读硕士、博士研究生 6 名。

　　电子邮箱：luyu4876@hotmail.com;

　　代表作：

　　1.Jian Xu#; Bin Wang#; Lei Fu; Hui Zhu; Shaochen Guo; Haihong Huang; Dali Yin; Ye Zhang; Yu Lu*. In Vitro and In Vivo Activities of the Riminophenazine TBI-166 against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2019, 63(5): e02155-18.

　　2.Ye Zhang#; Hui Zhu#; Lei Fu; Bin Wang; Shaochen Guo; Xi Chen; Zhongquan Liu; Haihong Huang; Tianjian Yang; Yu Lu*. Identifying Regimens ContainingTBI-166, a New Drug Candidate against Mycobacterium tuberculosis In Vitro and In Vivo, Antimicrobial Agents and Chemotherapy, 2019, 63(7): e02496-18.

　　3. Hui Zhu#; Lei Fu#; Bin Wang; Xi Chen; Jiaojie Zhao; Haihong Huang; Yu Lu*. Activity of Clofazimine and TBI-166 against Mycobacterium tuberculosis, in different administration intervals in mouse tuberculosis models. Antimicrobial Agents and Chemotherapy, 2021, 65(4): e02164-20.

　　4.Shaochen Guo#; Lei Fu#; Bin Wang; Xi Chen; Jiaojie Zhao; Mingliang Liu*; Yu Lu*. In vitro and in vivo antimicrobial activities of a novel piperazine-containing benzothiazinones candidate TZY-5-84 against Mycobacterium tuberculosis. Biomedicine & Pharmacotherapy, 2020, 131: 110777.

　　5. Minghao Hu#; Lei Fu; Bin Wang; Jian Xu; Shaochen Guo; Jiaojie Zhao; Yuanyuan Li; Xiaoyou Chen*; Yu Lu*. Genetic and Virulence Characteristics of Linezolid and Pretomanid Dual Drug-Resistant Strains Induced from Mycobacterium tuberculosis in vitro. Infection and Drug Resistance, 2020, 13: 1751-1761.